Literature DB >> 21320716

Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of venous thromboembolism in Chinese population.

Yan-Yan Li1, Zhen-Guo Zhai, Yuan-Hua Yang, Bao-Sen Pang, He-Yao Wang, Wei Zhang, Lan Zhao, Jun Wang, Chen Wang.   

Abstract

INTRODUCTION: Endothelium derived nitric oxide (NO) is a key mediator of vascular homeostasis. Endothelial nitric oxide synthase (eNOS) gene, by affecting the expression and functional activity of the eNOS enzyme, thereby reducing NO availability, may be implicated in venous thromboembolism (VTE). We investigated the eNOS G894T polymorphism in VTE patients in the Chinese population.
MATERIALS AND METHODS: A case-control study was conducted in a general hospital. Blood samples, collected from 462 consecutive patients with VTE and 462 healthy controls, were used for DNA extraction. Single nucleotide polymorphisms (SNP) of eNOS (894G/T) were determined by allele specific-polymerase chain reaction (ARMS-PCR) analysis.
RESULTS: The eNOS 894G/T polymorphism alleles distribution was in agreement with the principle of Hardy-Weinberg equilibrium. The prevalence of homozygote, heterozygote and pathological homozygote for the eNOS G894T polymorphism in VTE patients was 79.7%, 18.1% and 2.2%, respectively (controls: 86.6%,12.3% and 1.1%). T allele distribution in the VTE (11.3%) and especially the male VTE patients (12.5%) was more common than in healthy controls (7.3%). The frequency of GT+TT genotype was significantly higher among the age≤55years patients in VTE group than in controls (20.1% vs. 12.2%, P=0.033).
CONCLUSION: Our result demonstrates that the 894G/T polymorphism variant of eNOS is a risk factor for VTE in Chinese population.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320716     DOI: 10.1016/j.thromres.2010.11.034

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  Progress in research into the genes associated with venous thromboembolism.

Authors:  Lian-Xing Zhao; Bo Liu; Chun-Sheng Li
Journal:  World J Emerg Med       Date:  2015

2.  Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.

Authors:  Jeffrey A Kline; Cassandra L Hall; Alan E Jones; Michael A Puskarich; Ronald A Mastouri; Tim Lahm
Journal:  Am Heart J       Date:  2017-01-27       Impact factor: 4.749

3.  Promoter polymorphism T-786C, 894G→T at exon 7 of endothelial nitric oxide synthase gene are associated with risk of osteoporosis in Sichuan region male residents.

Authors:  Zuchao Gu; Yu Zhang; Guixing Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Risk indicators for venous thrombosis in first-degree relatives of patients with recurrent venous thromboembolism in Chinese.

Authors:  Lianxing Zhao; Chunsheng Li; Rui Shao; Yingying Fang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  A targeted proteomics investigation of the obesity paradox in venous thromboembolism.

Authors:  Vincent Ten Cate; Thomas Koeck; Jürgen Prochaska; Andreas Schulz; Marina Panova-Noeva; Steffen Rapp; Lisa Eggebrecht; Michael Lenz; Julia Glunz; Madeleine Sauer; Raff Ewert; Michael Halank; Thomas Münzel; Stefan Heitmeier; Miguel A Andrade-Navarro; Karl J Lackner; Stavros V Konstantinides; Kirsten Leineweber; Philipp S Wild
Journal:  Blood Adv       Date:  2021-07-27

6.  Genetic polymorphism of NOS3 with susceptibility to deep vein thrombosis after orthopedic surgery: a case-control study in Chinese Han population.

Authors:  Jizheng Qin; Jin Dai; Zhihong Xu; Dongyang Chen; Jianghui Qin; Dongquan Shi; Huajian Teng; Qing Jiang
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

7.  Challenges imposed by minor reference alleles on the identification and reporting of clinical variants from exome data.

Authors:  Mahmoud Koko; Mohammed O E Abdallah; Mutaz Amin; Muntaser Ibrahim
Journal:  BMC Genomics       Date:  2018-01-15       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.